The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A genotype-directed study to optimize dosing of irinotecan according to the UGT1A1 genotype.
Federico Innocenti
Other Remuneration - Mayo Foundation
Ravi Salgia
No relevant relationships to disclose
Jacqueline Ramirez
No relevant relationships to disclose
Linda A. Janisch
No relevant relationships to disclose
Samir D. Undevia
No relevant relationships to disclose
Larry House
No relevant relationships to disclose
Soma Das
No relevant relationships to disclose
Kehua Wu
No relevant relationships to disclose
Michelle Turcich
No relevant relationships to disclose
Robert de Wilton Marsh
No relevant relationships to disclose
Theodore Karrison
No relevant relationships to disclose
Michael L. Maitland
No relevant relationships to disclose
Richard L. Schilsky
Consultant or Advisory Role - GlaxoSmithKline; Merck
Honoraria - GlaxoSmithKline; Merck
Mark J. Ratain
Other Remuneration - Mayo Foundation